Exploring the atypia of undetermined significance: Malignant ratio, ThyroSeq v3 positive call rate, molecular-derived risk of malignancy, and risk of malignancy as possible quality metric tools in thyroid cytology.
Cancer Cytopathol
; 132(8): 491-498, 2024 Aug.
Article
de En
| MEDLINE
| ID: mdl-38594180
ABSTRACT
BACKGROUND:
The atypia of undetermined significance (AUS) category is heterogeneous, leading to variations in its use. To prevent excessive usage, the AUS rate should be ≤10%. Although this recommendation aims to maintain diagnostic quality, it lacks supporting data. The AUSMalignant (AUSM) ratio has been proposed as a metric tool to evaluate AUS use. Furthermore, integrating ThyroSeq v3 (TSV3) positive call rate (PCR) and the molecular-derived risk of malignancy (MDROM) have been put forward as performance improvement tools. The authors reviewed their AUSM ratios, TSV3 PCR, MDROM, and ROM.METHODS:
Thyroid aspirates evaluated in the laboratory (from August 2022 to September 2023) by seven cytopathologists (CPs) were identified. AUSM ratio, MDROM, ROM, and TSV3 PCR results for the laboratory and each CP were recorded and analyzed.RESULTS:
A total of 2248 aspirates were identified (462 AUS and 80 malignant). The AUSM ratio for the laboratory was 5.8 (CPs range, 2.8 to 7.3). The TSV3 PCR for the laboratory was 23% (CPs range, 11% to 41%). The MDROM for the laboratory was 19% (CPs range, 9% to 31%), whereas the ROM was 36% (CPs range, 29% to 50%). Linear regression analysis of AUSM ratio versus TSV3 PCR and MDROM demonstrated a moderate positive correlation but a weak negative correlation to the ROM. Deviations from established targets were attributed to multiple factors.CONCLUSION:
The findings of this study underscore the importance of using a combination of metrics to evaluate diagnostic practices. By dissecting the practice patterns of each CP, the authors can measure different aspects of their performance and provide individualized feedback.Mots clés
Texte intégral:
1
Collection:
01-internacional
Base de données:
MEDLINE
Sujet principal:
Tumeurs de la thyroïde
/
Nodule thyroïdien
Limites:
Female
/
Humans
Langue:
En
Journal:
Cancer Cytopathol
Année:
2024
Type de document:
Article
Pays d'affiliation:
États-Unis d'Amérique